Trandolapril

Research use only, not for human use.

Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that is hydrolysed to the active diacid trandolaprilat.

Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that is hydrolysed to the active diacid trandolaprilat.

Trandolapril (0.02 mM, 1 mM; 3 d) inhibits cell growth and induces cell apoptosis, increases the percentage of apoptotic cells in K562 cell line. Apoptosis Analysis Cell Line:K562, KU812, U937 and HL60 Concentration:0-2 mM Incubation Time:0, 1, 2, 3 days Result:Inhibited K562, KU812, U937 at 1 mM and inhibited HL60 at 0.02 mM.

Trandolapril (3 mg/kg/day; p.o.; 7 d) reduces renal fibrosis in obstructive nephropathy in mice, by inhibiting renal interstitial matrix expression and myofibroblast activation, decreasing renal proinflammatory cytokine RANTES and TNF-α level.Trandolapril (0.3 mg/kg/day; p.o.; 4 weeks) improves arterial mechanics in rats, prevents arterial hypertrophy, collagen and cellular fibronectin accumulation.randolapril (0.3 mg/kg/day; p.o.; 4 months) exhibits a chronic anti-hypertension effects in rats, results in blood pressure decreasing.Trandolapril (0.25 mg/kg; p.o.; twice a day; 4 months) inhibits Atherosclerosis in the Watanabe Heritable Hyperlipidemic Rabbit. Animal Model:UUD (unilateral ureteral obstruction) model in Male CD-1 mice (18-22 g) Dosage:3 mg/kg Administration:Oral gavage; daily, for 7 days Result:Resulted in renal interstitial matrix expression (including fibronectin, type I, and type III collagen) decreasing, and inhibited myofibroblast activation by surprising a-smooth muscle actin (a-SMA) expression, decreased the RANTES (regulated on activation, normal T cell expressed and secreted) and TNF-α level.Animal Model:SHR model (spontaneously hypertensive rats, 4-week-old) Dosage:0.3 mg/kg Administration:Oral gavage; daily for 4 weeks Result:Reduced collagen content in the aortic media and increased ariterial distensibility up to about 80%.Animal Model:Watanabe heritable hyperlipidemic rabbit (3 months old)Dosage:0.25 mg/kg Administration:Oral gavage; twice a day; 9 months Result:Decreased in atherosclerotic involvement of the intimal surface, and also decreased cholesterol content in descending thoracic aorta.

RU44570

Metabolic Enzyme/Protease

ACE

——

——

——

87679-37-6

430.545

C24H34N2O5

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (232.27 mM)

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years